CPS

ALX Resources Corp. Intersects Uranium Mineralization at the Gibbons Creek Uranium Project, Athabasca Basin, Saskatchewan

Retrieved on: 
Monday, March 25, 2024
Lithium, CPS, Uranium, ALX, Eldorado Resources, Fracture, Mount, Radioactive decay, News, El Dorado, Weather, OTC, Australian Securities Exchange, Uranium mining

Vancouver, British Columbia--(Newsfile Corp. - March 25, 2024) - ALX Resources Corp. (TSXV: AL) (FSE: 6LLN) (OTC: ALXEF) ("ALX" or the "Company") is pleased to announce an update on the 2024 winter drilling program at its 100%-owned Gibbons Creek Uranium Project ("Gibbons Creek", or the "Project") located in the northern Athabasca Basin near the community of Stony Rapids, Saskatchewan.

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - March 25, 2024) - ALX Resources Corp. (TSXV: AL) (FSE: 6LLN) (OTC: ALXEF) ("ALX" or the "Company") is pleased to announce an update on the 2024 winter drilling program at its 100%-owned Gibbons Creek Uranium Project ("Gibbons Creek", or the "Project") located in the northern Athabasca Basin near the community of Stony Rapids, Saskatchewan.
  • Anomalous radioactivity and fracture-controlled uranium mineralization was intersected from 110.0 to 110.9 metres approximately 1.5 metres below the unconformity at 108.5 metres.
  • Uranium mineralization was observed as coatings on fractures in the drill core at 110.2 metres as well as other fractures between 110.0 and 110.9 metres.
  • Weather conditions remain satisfactory for the operation of equipment and personnel and the work is proceeding as scheduled.

RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients

Retrieved on: 
Tuesday, April 9, 2024
CPI, CPS, Disease, HNSCC, Patient, SAN, Inflammation, Pembrolizumab, HPV, AACR, CCR4, Therapy, PD-L1, Safety, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., April 09, 2024 (GLOBE NEWSWIRE) --  RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced safety and efficacy data from its ongoing Phase 2 trial of tivumecirnon in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab in the cohort of patients with advanced head and neck squamous cell carcinoma (HNSCC) whose disease progressed despite previous treatment with CPI therapy (CPI-experienced). The results were presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA.

Key Points: 
  • The results were presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA.
  • The AACR poster highlighted data from the 32-patient CPI-experienced HNSCC cohort in the trial evaluating tivumecirnon, an oral small molecule CCR4 antagonist designed to block the migration of regulatory T cells, in combination with pembrolizumab.
  • Patients in this cohort had heavily pretreated disease, with 69% of patients having received three or more (up to six) prior lines of treatment.
  • In the entire cohort, confirmed responses were observed in 5/32 patients (15.6%) regardless of PD-L1 or HPV status.

Consumer Portfolio Services Appoints Gateway to Lead Expanded Investor Relations Program

Retrieved on: 
Wednesday, April 3, 2024
Development, Machine learning, CPSS, Gateway, Gateway Conference, Conference, History, CPS, Gateway Group, AI

Gateway will work closely with CPS management to develop and deploy a comprehensive outreach and communications program.

Key Points: 
  • Gateway will work closely with CPS management to develop and deploy a comprehensive outreach and communications program.
  • Gateway will also assist in organizing roadshows and securing invitations to select financial conferences, including its annual Gateway Conference .
  • This performance has expanded our total managed portfolio to $3.2 billion, marking the largest amount in our history.
  • We look forward to working closely with the Gateway team to execute a comprehensive investor relations program that will allow us to improve our corporate profile, enhance our market position, and expand our shareholder base.”

Global Uranium Production to Increase as Prices Are Expected to Hit a 15 Year High

Retrieved on: 
Tuesday, April 2, 2024
Triple, CPS, Appaloosa, International Financial Reporting Standards, Transport, OTCQX, Party, Westinghouse, Count, Technical, International, PALM, PLS, GlobalData, Fertility, Stallion, Glacier Media, Climate change, COP28, STUD, Ice, OTCQB, FCU, Athabasca Basin, News, Handgun holster, Radioactive decay, TSX, NXE, NexGen, Mining, Conference, Growth, Conference of the Parties, Fission, FUU, BGO, Uranium mining

It added: "Kazakhstan is expected to deliver the highest uranium production growth in 2024, GlobalData says, driven by the planned higher output from the country’s largest uranium producer Kazatomprom.

Key Points: 
  • It added: "Kazakhstan is expected to deliver the highest uranium production growth in 2024, GlobalData says, driven by the planned higher output from the country’s largest uranium producer Kazatomprom.
  • The continuous ramp-up of Canada’s McArthur River uranium mine will also contribute to the global increase, it adds.
  • Despite a 5.1% dip in output in 2023 due to planned lower production from Kazatomprom, its output is expected to recover in 2024, with forecast production of 23.2kt.
  • It continued: “Meanwhile, global uranium production in 2024 will be further bolstered by continuous ramp-up of Canada’s McArthur River, which is aiming to produce 6.9kt of uranium (8.2kt of U3O8) for 2024.

Stallion Uranium Drilling Intersects Anomalous Radioactivity

Retrieved on: 
Tuesday, April 2, 2024
SRC, La Loche, QA/QC, CPS, TDEM, National Instrument 43-101, Coffer, Blue square, Uranium, Boron, Appaloosa, ICP-OES, Radioactive decay, HF, ICP-MS, HNO3, National instrument, Standards Council of Canada, Fracture, Green Square, BGO, Clay, Athabasca Basin

The survey data when compiled and modeled with all available historical data showed the key characteristics for potential uranium mineralization.

Key Points: 
  • The survey data when compiled and modeled with all available historical data showed the key characteristics for potential uranium mineralization.
  • To best refine drill targets Stallion utilized the latest technology to complete an advanced ground TDEM survey over the target area.
  • Stallion Uranium requests multi-element analysis by ICP-MS and ICP-OES using total (HF:NHO3:HClO4) and partial digestion (HNO3:HCl), boron by fusion.
  • The foregoing scientific and technical disclosures for Stallion Uranium have been reviewed by Darren Slugoski, P.Geo., VP Exploration, a registered member of the Professional Engineers and Geoscientists of Saskatchewan.

CPS Announces Renewal of $200 Million Credit Facility

Retrieved on: 
Monday, April 1, 2024
CPSS, CPS

LAS VEGAS, Nevada, April 01, 2024 (GLOBE NEWSWIRE) -- Consumer Portfolio Services, Inc. (Nasdaq: CPSS) (“CPS” or the “Company”) today announced that on March 29, 2024, it renewed its two-year revolving credit agreement with Ares Agent Services, L.P.

Key Points: 
  • LAS VEGAS, Nevada, April 01, 2024 (GLOBE NEWSWIRE) -- Consumer Portfolio Services, Inc. (Nasdaq: CPSS) (“CPS” or the “Company”) today announced that on March 29, 2024, it renewed its two-year revolving credit agreement with Ares Agent Services, L.P.
    Loans under the renewed credit agreement will be secured by automobile receivables that CPS now holds, will originate directly, or will purchase from dealers in the future.
  • CPS may borrow on a revolving basis through March 31, 2026, after which CPS will have the option to repay the outstanding loans in full or to allow them to amortize through March 31, 2028.

Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates

Retrieved on: 
Friday, March 29, 2024
CPS, Patient, Lung cancer, IND, Infection, Cancer, Investment, Cisplatin, Paclitaxel, Melanoma, Marketing, RNA, New chemical entity, Gentlemen's agreement, NRDL, Food, Therapeutic Goods Administration, Biologics license application, Insurance, Research, Junshi, National Medical Products Administration, TGA, FDA, NMPA, Tablet, COVID-19, NPC, Spacecraft, DSM-IV codes, Dacarbazine, Axitinib, Total, Pharmaceutical industry

SHANGHAI, China, March 29, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial results for the full year of 2023 and provided corporate updates.

Key Points: 
  • SHANGHAI, China, March 29, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its financial results for the full year of 2023 and provided corporate updates.
  • Total research and development (“R&D”) expenses were approximately RMB1,937 million in 2023, representing a decrease of approximately 19% compared to 2022.
  • Loss attributable to owners was RMB2,282 million in 2023, representing a decrease of RMB104 million compared to the previous year.
  • This application was later approved for marketing in December 2023, marking the first and only approved perioperative therapy for lung cancer domestically.

Patriot Glass Solutions, a Subsidiary of C-Bond Systems, Receives Purchase Order to Install C-Bond Ballistic-Resistant System at CPS Energy Headquarters in San Antonio

Retrieved on: 
Monday, March 25, 2024
UL, Level 2, CPS, SAN, BRS, School, Glass, Justice, OTC, UL (safety organization), Safety, Government, Printed circuit board

SAN ANTONIO, March 25, 2024 (GLOBE NEWSWIRE) -- C-Bond Systems (the “Company” or “C-Bond”) (OTC: CBNT), a developer and marketer of glass strengthening solutions for enhanced safety, announced today that its Patriot Glass Solutions subsidiary has received a purchase order to install its C-Bond BRS (ballistic-resistant system) at CPS Energy’s headquarters in San Antonio.

Key Points: 
  • SAN ANTONIO, March 25, 2024 (GLOBE NEWSWIRE) -- C-Bond Systems (the “Company” or “C-Bond”) (OTC: CBNT), a developer and marketer of glass strengthening solutions for enhanced safety, announced today that its Patriot Glass Solutions subsidiary has received a purchase order to install its C-Bond BRS (ballistic-resistant system) at CPS Energy’s headquarters in San Antonio.
  • Patriot Glass Solutions also previously installed C-Bond Secure, its forced entry-resistant film system, at the energy company’s headquarters.
  • Patriot Glass Solutions also offers forced entry-resistant film, applied with its proprietary glass strengthener, called its C-Bond Secure product.
  • To see a demonstration of Patriot Glass Solutions’ security products, watch our video at: https://bit.ly/3l93oZV
    For more information about Patriot Glass Solutions’ products, please call 844-602-2663 or email Michael Wanke at [email protected] .

CPS Announces $50.0 Million Securitization of Residual Interests

Retrieved on: 
Friday, March 22, 2024
CPSS, CPS, Sale, Security (finance)

LAS VEGAS, Nevada, March 22, 2024 (GLOBE NEWSWIRE) --  Consumer Portfolio Services, Inc. (Nasdaq: CPSS) (“CPS” or the “Company”) today announced the closing of a $50.0 million securitization of residual interests from previously issued securitizations.

Key Points: 
  • LAS VEGAS, Nevada, March 22, 2024 (GLOBE NEWSWIRE) --  Consumer Portfolio Services, Inc. (Nasdaq: CPSS) (“CPS” or the “Company”) today announced the closing of a $50.0 million securitization of residual interests from previously issued securitizations.
  • In the transaction, a qualified institutional buyer purchased $50.0 million of asset-backed notes secured by an 80% interest in a CPS affiliate that owns the residual interests in five CPS securitizations issued from January 2022 through January 2023.
  • The transaction was a private offering of securities, not registered under the Securities Act of 1933, or any state securities law.
  • All of such securities having been sold, this announcement of their sale appears as a matter of record only.

Skyharbour’s Partner Company North Shore Uranium Completes Maiden Drill Program and Identifies Elevated Radioactivity, Fault Zones and Alteration at Falcon Project

Retrieved on: 
Wednesday, March 20, 2024
Diamond, QA/QC, CPS, Boron, Plagioclase, Property, Copper, Lead, SMDI, P12, Quality assurance, JNR, CAD, National Instrument 43-101, Analytic, Arsenic, Quality control, Shore, Vanadium, P03, Vein, Fracture, News, National instrument, Magnetism, Denison Mines, P08, Uranium, Molybdenum, EM, Radioactive decay, NSR, Nickel, Cobalt, Athabasca

The combination of the spatial relationship between the graphitic horizon, the structure, alteration and the radioactivity upgrade this target.

Key Points: 
  • The combination of the spatial relationship between the graphitic horizon, the structure, alteration and the radioactivity upgrade this target.
  • This lower fault zone displayed strong bleaching (illite+/-sericite) clay alteration, strong hematite and chlorite along fractures and patchy silica alteration.
  • Nine of the claims are from Skyharbour’s original South Falcon Uranium Project and the remaining two claims are from Skyharbour’s Foster River Project.
  • North Shore will be the operator of the exploration programs during the earn-in stage and for the joint venture if formed.